Core Viewpoint - Cloud-based innovative pharmaceutical company, CloudTop New Medicine, reported strong mid-year performance for the period ending June 30, 2025, showcasing robust growth and a solid foundation for becoming a leading global Biopharma company [1] Financial Performance - Total revenue for the first half of 2025 reached RMB 446 million, a significant increase of 48% year-on-year [1] - Operating expenses as a percentage of revenue decreased by 40.1 percentage points, indicating improved operational efficiency [1] - Non-IFRS total loss narrowed by 31%, with a cash reserve of RMB 1.6 billion, bolstered by a recent fundraising of HKD 1.553 billion [1] Product Performance - The kidney disease treatment product, Nefukang, achieved sales of RMB 303 million in the first half, a remarkable increase of 81% year-on-year [2] - Sales for Nefukang from January to August reached RMB 825 million, with August alone generating RMB 520 million [2] - The antibiotic drug, Yijia, also showed steady growth with sales of RMB 143 million, a 6% increase year-on-year [2] Strategic Initiatives - The company is advancing its "dual-engine" strategy, focusing on both commercialization and R&D to establish a competitive global pipeline [3] - The personalized tumor therapeutic vaccine, EVM16, has initiated its first human clinical trial in China, with positive preliminary data [3] - The CAR-T project, EVM18, is expected to start clinical trials by the end of 2025, while the new generation BTK inhibitor, EVER001, is progressing well in clinical trials [4] Future Outlook - The company aims to achieve annual sales of RMB 1.6 to 1.8 billion and expects to turn operationally profitable in the second half of 2025 [1][2] - The strategic investment in I-Mab enhances the company's global positioning in next-generation tumor immunotherapy [4] - The company targets a sales peak exceeding RMB 25 billion in the future, driven by its innovative platforms and product synergies [5]
云顶新耀2025上半年营收增长48% 预计全年营收16-18亿